Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting
Go back to Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting| SYNACOR (NASDAQ: SYNC) | Delayed: 2.19 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.19 | 52 Week High | $3.98 | |||
| Open | $38.50 | 52 Week Low | $1.33 | |||
| Day High | $2.19 | P/E | N/A | |||
| Day Low | $2.19 | EPS | $-0.02 | |||
| Volume | 136,163 | |||||
